Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging of a Patient with Squamous Cell Carcinoma of Prostate

Primary squamous cell carcinoma is an uncommon tumor of the prostate gland. We report a 77-year-old male patient with urinary frequency and constipation. Fine needle biopsy from prostate was suspicious of squamous cell carcinoma of the prostate. Whole body positron emission tomography/computed tomography scan revealed high fluorodeoxyglucose uptake in prostate gland. Transurethral resection confirmed the diagnosis. In contrast to prostatic adenocarcinoma, high fluorodeoxyglucose accumulation was observed in the primary tumor of the prostate gland

Characteristics of sildenafil erections in healthy young men

Abstract Aim: To determine the effect of sildenafil citrate on the nocturnal penile erections (i.e. time to onset, the duration of erection, and the interval between first and second erections) of healthy young men. Methods: Twenty-two potent men, 23-29 years old, were recruited for the study. All subjects completed three sessions over consecutive nights using the RigiScan monitoring device (Dacomed, Minneapolis, USA). After a first night of adaptation, night 2 records were their baseline values, and on night 3 they received 100 mg of sildenafil citrate. Statistical comparisons were done between the second and third night data. Results: The mean time to onset of the first erection with sildenafil citrate was (34 ± 18) min, whereas it was (74 ± 24) min (P < 0.001) without sildenafil citrate. The number of erections observed during the first 5 h after sildenafil citrate medication was 3.6 ± 0.5 in contrast to 2.4 ± 0.5 with no medication (P = 0.001). The interval between first and second erections was shorter with sildenafil citrate: (52 ± 26) min vs. (85 ± 34) min (P = 0.01). The duration of the last erection was statistically significantly longer with the sildenafil citrate: (64 ± 33) min vs. (42 ± 28) min (P < 0.01). Conclusion: Healthy young men achieved erection within 34 min after sildenafil citrate administration, which is shorter than the 1 h interval proposed by the manufacturer. The interval between the first and second erections was shorter and the duration of the last nocturnal erection was longer. (Asian J Androl 2005 Dec; 7: 395-398

Adrenal Lymphangioma Mimicking Renal Cyst: A Case Report and Review of the Literature

We present a case of a 44-year-old female who was evaluated for left recurrent flank and abdominal pain. Abdominal ultrasonography demonstrated a large cystic mass on the upper pole of the left kidney. Magnetic resonance imaging showed a large, homogenous cystic mass measuring 8.5 × 9.5 cm with well-defined contours, being hypointense on T1-weighted images and hyperintense on T2-weighted images on the upper pole of the left kidney without a distinct plan between adrenal gland. According to clinical and radiological findings, surgical excision was carried out with a subcostal flank incision. Histologic and immunohistochemical examination demonstrates that the definite diagnosis is cystic lymphangioma of the left adrenal gland. Adrenal lymphangioma is a very rare lesion. This is the unique case of an adrenal lymphangioma considered as a renal cyst because of its radiological appearance

Who is in your trial? Improving the reporting of participant characteristics in trial protocols and results

‘Without data, you’re just another person with an opinion.’So said W. Edwards Deming, whose work on industrial quality-control methods helped post-war Japan’s economic recovery and that of the American car industry in the 1980s. It is doubtful that any seasoned trialist would argue with Dr. Deming. After all, generating data is trialists’ bread and butter.We do trials because we believe that our data will help patients, healthcare professionals, guideline developers, policymakers and others to make informed, evidence-based healthcare decisions. Trial data, ideally from more than one trial, reduces clinical uncertainty and improves confidence in a decision.But what if these data say little or nothing about who was in the trial beyond the fact that everyone met the inclusion criteria? Imagine a trial in the UK that aimed to reduce maternal mortality. Future users of the trial results will likely need to know (at least) the age, socioeconomic status and ethnicity of the people in the trial because maternal mortality is higher in older, socioeconomically disadvantaged and, in particular, Black women [1]. Older or socioeconomically disadvantaged or Black women have a great deal to gain from improved care, with those sharing all three characteristics standing to benefit the most.If this trial showed a benefit for those receiving the intervention, a UK policymaker could be expected to ask whether the intervention also worked for Black women and/or women who are older or experiencing socioeconomic disadvantage. Does it work for them too? An intervention that doesn’t help all women will widen, not reduce, inequity. Without explicit data on who is in the trial, users of the results are left to speculate. We are back to opinions.It is not difficult to find examples of trials that do not say much about who is in the trial beyond stating that participants met the clinical eligibility criteria [2,3,4,5,6]. Buttery and colleagues for example reported that of the 24 trials in their sample, only 12 reported ethnicity and only four reported a measure of socioeconomic status [4]. Of those not reporting ethnicity, none reported the lack of these data as a limitation and only one of the 21 trials not reporting socioeconomic status did the same. Fortunately, the editors of some journals have taken positive steps to help reduce the likelihood of this happening in the future [7, 8]. Today, we announce some changes Trials is making to do the same

Development of a prospective data registry system for retrograde intrarenal surgery in renal stones: Turkish academy of urology prospective study group (ACUP study)

OBJECTIVE:We aimed to report the development of a prospective data registry by generating a retrograde intrarenal surgery (RIRS)-specific electronic case report form (eCRF), which can be used by multiple centers in Turkey.MATERIAL AND METHODS:The Stone Disease Study Group of Turkish Urology Academy developed a template for the necessary data to be collected, which was then implemented within a dedicated server. Urologists from different universities, research and training centers, and private hospitals were invited to participate in this data registry. Each urologist was provided with a unique username and password after they agreed to participate in the study.RESULTS:In March 2015, the development of the eCRF was completed, and the server was opened for data input in April 2015. We started a prospective clinical data registry for all patients undergoing RIRS for renal stone(s) in 15 participating hospitals. Until the end of June 2016, 1112 RIRSs on 1264 patients have been included in the dataset.CONCLUSION:The easy-to-use eCRF specifically developed for RIRS was first of its kind in Turkey. This prospective data registry harvests important data that will be used to identify real-world demographic, clinical and operative data of patients with renal stone who undergo RIRS in various urology departments throughout Turkey. The results of this dataset will be presented in various papers.Turkish Association of Urolog

Testiküler kitlenin nadir sebebi: Fıtık eşliğinde paratestiküler liposarkom

Yumuşak dokunun sık gözlenen tümörü olan liposarkomun paratestiküler yerleşimi oldukça nadir görülmektedir. Sıklıkla ekstrape- ritoneal yağ dokusundan köken alan bu tümörler distale doğru korda ait yağ dokusuyla devam etmektedir. Tanı; genellikle operasyon sırasında şüphe üzerine histopatolojik değerlendirme ile konur. Bu yazıda testiküler kitle nedeni ile opere edilen paratestiküler lipo- sarkom ve beraberinde inguinal hernisi olan olgu sunulmuştu